Acetaminophen and infant health face new trial results and FDA petition

A randomized controlled trial involving nearly 4,000 infants in New Zealand has found no significant difference between the use of acetaminophen and ibuprofen regarding the development of eczema or hospitalizations for respiratory issues like bronchiolitis and asthma. The PIPPA Tamariki trial, which monitored infants for one year, aimed to address concerns raised by previous observational studies that suggested links between early acetaminophen exposure and wheezing or asthma.

In a separate development, the organization Children's Health Defense has filed a petition with the U.S. Food and Drug Administration (FDA). The petition requests a ban on over-the-counter Infants’ Tylenol and calls for boxed warnings on acetaminophen products for children under age 6. The group cites various studies to argue for potential links between the medication and autism spectrum disorder, as well as concerns regarding neurodevelopmental risks and dosing safety for very young children.